top of page



Philippe Peyre


President of Future4care

Born in 1951, Philippe Peyre is a graduate of the Ecole Polytechnique and began his career in consulting with Bossard, where he became Managing Director.

In 1997, following the sale of the Bossard Group to the Cap Gemini Group, he became a member of the Executive Committee of Bossard Gemini Conseil.

In 1998, on returning to Rhône Poulenc, he joined the Pharma business and became Senior Vice-President, Special Projects.

In 1999, when Aventis was formed, he was appointed Senior Vice-President "Head of Integration". He led the integration of Hoechst and Rhône-Poulenc; in 2002, when the Aventis Group's governance system was changed, he became the Group's Company Secretary.

In 2004, when Aventis was acquired by Sanofi, he was appointed Senior Vice President General Affairs, in charge of overseeing the Group's support functions (IS, Purchasing, Real Estate, HSE, CSR, Security). He is a member of the Sanofi-Aventis Group Executive Committee.

In 2008, he was also appointed Secretary to the SANOFI Board of Directors.

In 2009, he was put in charge of the Group's transformation plan.

From 2012 to 2023, he is General Secretary of SANOFI.

In 2018, he became Director of the Larena/Pileje Group.

In June 2021, he becomes Chairman of Future4Care.

Emmanuel Nere.jfif

Bio to be updated soon

Emmanuel Néré


Director of Innovation at Generali

Fabrice Denis.png

Fabrice Denis


President of the INeS

Pr Denis is President of the Institute for Smarthealth (INeS) and is a radiation-oncologist (MD) in the Centre de Cancérologie de la Sarthe (Le Mans, FRANCE).

He is Associate Professor of e-health at the Medicine School of Paris Cité.

He has a PhD in Life Sciences and is associate researcher in the French academic National Center of Scientific Research (CNRS) in Rouen.

He is an expert in chaos theory applied to cancer. He is a member of the American Society of Clinical Oncology (ASCO) and past-President of the French National Syndicate of Radiation-Oncologists.

Until now, he has authored more than 140 peer reviewed scientific papers and book chapters.

He is advisor for governments and industrial companies as e-health expert.

He has pioneered research on patient self-reporting of symptoms for patient surveillance.

He created the first web-application in the world (MoovcareTM) which demonstrated evidence of survival benefit in clinical trials in cancer patient’s follow-up using patient-reported outcome and acquired reimbursement in 2020. He also created, a triage webapp which was used by near 15 millions users in France during COViD-19 pandemic to reduce emergency calls saturation.

He is member of the European Society of Medical Oncology task force and is co-author of the International Guidelines of ePROMs in clinical practice.

He received national and international awards for his research on e-health and cancer. He received the 2020 personality of the year's award at the BFM national health trophies.

He also designed self-assessment and IA applications that aimed to prevent and early detect disease in childs (Malo), adults and elderly (Tempoforme/Age Advisor).

He is operating partner in the fund Nextstage AM.

Olivier Guerin.png

Olivier Guérin


Vice-President of Future4care and member the Scientific and Ethic Council

Director of the Rehabilitation, Autonomy and Ageing Unit: Professor Olivier GUERIN University Professor - Geriatric Hospital Practitioner, MD, PhD Olivier Guerin was appointed University Professor in 2011 and Head of the Acute and Therapeutic Geriatrics Department in 2013.

He has been Head of the Rehabilitation, Autonomy and Ageing Unit since 2015. He is strongly committed to digital health and independent living, and has worked with his teams to set up evaluation and experimentation platforms dedicated to these areas.

He was deputy mayor of Nice, responsible for health, prevention and support for the loss of autonomy, and metropolitan councillor from April 2014 to June 2020, in charge of issues relating to health, prevention and autonomy.


He is also active at national level, as President of the French Geriatrics and Gerontology Society in 2018 and as an expert for the Court of Auditors on the prevention of loss of autonomy in 2020.

He is also involved in molecular biology research alongside Professor Eric Gilson at the Nice Cancer and Ageing Research Institute (IRCAN, a university/INSERM/CNRS research centre).

He became a member of the President of the French Republic's Scientific Advisory Board as part of the COVID health crisis in 2020.


Since July 2023, Professor Olivier Guerin has been President of the National Professional Council - Geriatrics Specialty (CNP-SG).

David Naccache_edited_edited.jpg

David Naccache is a professor at Ecole normale supérieure (Paris) and an Honorary professor at the University of Luxembourg. He is a forensic expert accredited by the French Cour de cassasion and by various other tribunals. He is the inventor of about 200 patent families and the author of about 200 scientific papers in the areas of security and cryptology. He is currently working on reverse-engineering, data extraction and the automated detection of flaws in implementations. He is a fellow of IACR, a member of the Institut universitaire de France and a doctor honoris causa of Romania's Academia Tehnică Militară. He supervised about 30 PhDs in the field.

David Naccache


Researcher in information security

230105 Aiman Ezzat bureau Tilsitt.jpg

Aiman Ezzat is CEO of the Capgemini Group since May 20, 2020. Since assuming the role, Aiman has directed the integration of Altran and reinforced Capgemini’s position as a leading responsible organization, notably committing to becoming a net zero business by 2040. With more than 25 years’ experience at Capgemini, he has developed a deep knowledge of the Group’s main businesses and has worked in many countries, notably the UK and the US, where he lived for more than 15 years. During his tenure as COO (from 2018 to 2020) and prior to this as CFO, from 2012 to 2018, Aiman reinforced both the Group’s position as a global leader as well as its financial resilience. Aiman has a dual background in chemical engineering and management. He holds a MBA from the Anderson School of Management at UCLA. Aiman is also on the Air Liquide Board of Directors and is a member of the Business Council and the European Round Table for Industry.”

Aiman Ezzat

Chief Executive Officer

of Capgemini Group

Christel Heydemann 2_edited.jpg

Christel Heydemann

Chief Executive Officer

at Orange

Christel Heydemann was appointed Chief Executive Officer of the Orange Group on 4 April 2022.

She began her career in 1997 at Boston Consulting Group. In 1999, she joined Alcatel where she was entrusted with a range of roles and responsibilities, specifically in the context of the merger of Alcatel and Lucent.

In 2008, she was appointed to Alcatel-Lucent’s Executive Committee as Sales Director for France and promoted in 2011 as Director of Human Resources and Transformation.

In 2014, Christel Heydemann joined Schneider Electric as the Director of Strategic Alliances before being appointed as Senior Vice President Corporate Strategy & Alliances in 2016. In April 2017 she becomes Executive Vice President of Schneider Electric France and subsequently Executive Vice President Europe Operations in May 2021. She was also a member of the Executive Committee of Schneider Electric until the beginning of 2022.

Christel Heydemann is now CEO of the Orange Group, having been a member of the Board of Directors since 2017.

She graduated from the Ecole Polytechnique (France, 1994) and the Ecole Nationale des Ponts et Chaussées (France).

New Paul Hudson - 10.20 (1).jpg

Paul Hudson

Chief Executive Officer

at Sanofi

Paul Hudson is reshaping Sanofi into a modern healthcare company with the ambition to transform the practice of medicine. Driven by a purpose to chase the miracles of science to improve people’s lives, Paul and the Sanofi teams are focusing efforts to discover, develop and make accessible breakthrough medicines and vaccines for people around the world. Under Paul’s leadership, the company has prioritized social impact by putting diversity, equity and inclusion, as well as health and environmental sustainability, at the core of its long-term strategy.  


Before joining Sanofi, Paul was CEO of Novartis Pharmaceuticals from 2016 to 2019, and a member of the Novartis Executive Committee. His career in healthcare has spanned the globe, with assignments in the US, Japan and Europe. Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of president, AstraZeneca US and executive vice president, North America. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK. 


Paul holds a degree in economics from Manchester Metropolitan University in the UK, and in July 2018 his alma mater awarded him an honorary Doctor of Business Administration for his achievements in industry. 

Jean Laurent Granier.jfif

Jean-Laurent Granier is Chairman & CEO of Generali France, Member of the Group Management Committee of Generali S.p.A, Chairman of Europ Assistance Group.

From September 1st, 2022, Country Manager France, Europ Assistance & Global Business Activities.

He is a graduate of Ecole Polytechnique and ENSAE and a member of the French Institute of Actuaries. Previously he was CEO of the Mediterranean and Latin America Region, Chairman & CEO of AXA Global P&C, Member of the AXA Management Committee, overseeing the worldwide operations of AXA Corporate Solutions.

Jean-Laurent Granier

Chief Executive Officer at Generali France


Agnès is a graduate of IEP Strasbourg and ESCP, and holds a DEA in International Economic Law,

Agnès began her career with the Vivendi Group, where she held various positions before becoming the Group's Director of Innovation.

In 2012, she joined Orange as Director of Strategy and Business Development for Orange France. 

In 2019, she will become Director of Strategy for the Orange Group.

Agnès de Leersnyder has been Managing Director of Future4care since June 2021.

Agnès De Leersnyder


CEO of Future4care

Fabrice Bartolomei 2.jpg

Fabrice Bartolomei

Director, Clinical Neurophysiology Department,

Hôpital de la Timone, PA

Neurologist specialised in epilepsy, Fabrice Bartolomei is a professor at the University of Aix-Marseille, where he heads the Department of Epileptology and Clinical Neurophysiology.

He is also a member of the INSERM U1106 research unit (DYNAMAP team).

He is particularly involved in the pre-surgical assessment of patients with drug-resistant epilepsy and is a world leader in the analysis of stereo-EEG (intracerebral EEG) recordings.

He has published over 300 studies in the field of epilepsy, notably on the concept of 'epileptogenic networks'.

He has long promoted the use of quantified signal analysis in EEG/SEEG and is the inventor of the "Epileptogenicity Index", a method for evaluating the epileptogenicity of brain regions.

Fabrice Bartolomei is the coordinator of an RHU (Hospital-University Research, Investissements d'avenir/ANR) "EPINOV" (2018-2023) based on the study of large-scale individualised modelling in epilepsy surgery and one of the three principal investigators of the European Union ERC grant "Synergy, Galvani" on the study of brain stimulation by weak electric fields in epilepsy (2020-2026).

Founding member of the company VB-TECH (startup).

Tanja-Dowe (1).webp

Tanja is a Managing Director at Angelini Ventures. Prior to joining Angelini Ventures, Tanja was the CEO of Debiopharm Innovation Fund in Lausanne, Switzerland, where she built a portfolio of 17 digital health and data driven R&D tech companies, and consolidated a legacy portfolio of diagnostics investments.

Before her career in start-up investments, Tanja was the Managing Partner of Innomedica Ltd, a boutique strategy and transaction consulting company in life sciences, and a founder-CEO of a market research agency BioSolutions INT.

During her career, Tanja has worked with over 90 healthtech companies globally, leading to broad experience in innovative product development, commercial strategies, and building winning teams.

Tanja is an experienced board member and chairwoman with a track record of successful M&A exits.

She holds an MSc in Applied Microbiology and Biochemistry from Helsinki University of Technology.

Tanja Dowe

Managing Director 

Angelini Ventures

Maximilien Levesque_edited_edited.jpg

Maximilien Levesque

CEO & Cofounder of AQEMIA

Maximilien, 39 years old, owns a Ph.D. in quantum physics.

At 27, after doing research at Oxford and Cambridge, UK, he becomes a director and principal investigator at CNRS and École Normale Supérieure, Paris, where he works on the relationship between quantum and statistical physics.

In the following 6 years, he publishes around 50 scientific articles and receives several international prizes, including from the American Institute of Physics for the mathematical solution of an equation that remained unsolved for 40 years.

This work unlocks the rigorous, fast, and precise prediction of the efficacy of a potential drug. He cofounds AQEMIA in 2019 to discover drugs at scale thanks to its unique technology.

Aqemia is a pharma-tech company using quantum physics to fuel a generative AI to transform the drug discovery process.

With a unique proprietary technology that avoids the need for experimental data, our pipeline scales the drug discovery process at an unprecedented pace, generating an exhaustive number of new drug candidates.

jonathan baptista1.jpg

Jonathan co-founded DeepLife in 2019, establishing the first ever Digital Twin platform for cells and biological systems to support the life sciences industry.

He has multiple experiences in entrepreneurial companies, as well as over a decade of experience in technical roles in the aeronautical industry.

His education includes a degree in Business from the Mays School at Texas A&M University, as well as Bachelor's and Master's degrees in Complex System Engineering.

Jonathan Baptista

Co-founder & CEO Deeplife

Emmanuel Caeymaex.jpg

Emmanuel Cayemaex

Executive Vice President, Immunology and U.S. Solutions at UCB

Emmanuel Caeymaex is Executive Vice President, Immunology and U.S. Solutions at UCB, leading worldwide development and commercialization of innovative solutions that create unique value for people suffering from severe inflammatory and autoimmune disorders, such as psoriatic arthritis, axial spondyloarthritis, psoriasis, , rheumatoid arthritis, Crohn’s disease, and osteoporosis with ongoing research in hidradenitis suppurativa and systemic lupus erythematosus. He is also in charge of UCB’s corporate activities and operations in the United States and leads medical affairs and UCB’s digital business transformation initiative.

Since joining UCB in 1994, Emmanuel has been instrumental in advancing UCB’s transformation into a global biopharma company focused on patients with severe diseases. Prior to this role he led the CIMZIA® (certolizumab pegol) Global Patient Solutions team. Emmanuel formerly served as President of UCB Japan Co Ltd. from September 2006 to June 2011 and on the Global Operations Committee. He previously contributed to build UCB’s leadership position in epilepsy, successively as Global Brand Manager KEPPRA® (levetiracetam), UK Business Unit Head, and Vice President Global Marketing for Central Nervous System products. Prior to 1999, Emmanuel established and ran UCB’s operations in several Asia-Pacific markets for which he was awarded as Laureate of the Prince Albert Fund where he has served as President since May 2019. He also currently serves on the board of the Biotechnology Innovation Organization (BIO).

Emmanuel received a Business Engineer MSc degree from the University of Louvain, (Belgium), a Master’s in International Management from the Community of European Management Schools (and continued his executive leadership development journey at INSEAD.

Jean Philippe Vert 2.jpg

Jean Philippe Vert

Chief R&D Officer at OWKIN

Jean-Philippe Vert is Chief R&D Officer at Owkin, an AI Biotech company that uses AI to discover and develop treatments for unmet medical needs, and professor (on leave) at PSL University Mines Paris.

Before joining Owkin in 2022, he was a research scientist at Google Brain (2018-2022), where he led a research team working on core machine learning and computational biology; a research professor at ENS Paris’ mathematics Department (2016-2018); a Fullbright and Miller visiting professor at UC Berkeley’s Department of Statistics (2015-2016); a research team leader at the Curie Institute’s research center (2008-2018); a research professor and founding director of Mines ParisTech’s Centre for Computational Biology (2002-2018); and a research associate at Kyoto University’s Bioinformatics Center (2001-2002).

He graduated in applied mathematics from Ecole Polytechnique (1995) and Corps des Mines (1998), and received his PhD in mathematics from ENS Paris University (2001).

His research interest concerns the theory and practice of statistical machine learning and artificial intelligence to model complex data, and their applications in computational biology and medicine.

Pascal Roche.jfif

Pascal Roché graduated from HEC with a Master’s degree in Private Law (Paris II Assas) and a postgraduate degree in Economics and Organizational Strategy (Paris Dauphine). He also graduated from the Institut des Actuaires Français.

Pascal Roché began his career as a strategy advisor before joining the insurance sector in 1991, working as strategy director at UAP (now AXA France) before assuming responsibility for several operational departments for more than 10 years. Between 2000 and 2002, he was Deputy CEO of Axa France Services, then Director of Corporate Functions and a member of the Axa France executive committee. He joined Barclays in 2002, as CEO for France, then Spain and, at the same time, assumed worldwide responsibility for Premier clients and insurance and investments from 2008.

In June 2011, he became CEO of Ramsay Santé, the leading private hospital group in France. Following the successful takeover of Capio AB, he became Chair of the Capio AB Board of Directors in November 2018.

Pascal Roché

CEO Ramsay Santé

Charles Guepratte.png

Charles Guépratte

General Manager of FEHAP

Previously Chief Executive Officer of Nice University Hospital since 2016, Charles Guépratte was also involved in the Union des Hôpitaux pour les Achats (UniHA), of which he was President (2017-2022), as well as digital healthcare issues as President of the Groupement Régional d'Appui au Développement de la e-Santé (GRADeS PACA) (2018-2021).
A graduate of EHESP, his professional life has been built up in both the public and private sectors.
Firstly, in the public hospital sector, as Purchasing Director at Nancy University Hospital (2003-2004), then as Chief of Staff to the General Manager of the University Hospital, while also managing the Pont à Monsoon University Hospital (2005-2007).
He then moved to government service, as technical advisor for healthcare organization in the cabinet of the French Minister of Health and Sport, Roselyne Bachelot. In this capacity, he was involved in drafting the HPST law, as well as the palliative care development plan and the political appraisal of "Hôpital 2012" investment projects.
Working in the private sector, he was deputy CEO of the Institut Gustave Roussy (2009-2016), where he chaired the Executive Board of the Fondation Gustave Roussy, and participated in the international development of Gustave Roussy's activities as Chairman and CEO of SAS Gustave Roussy International (2015-2016).

Fabien Niel.png

Fabien Niel

Founder & CTO 

Quantiq IO

Fabien Niel is a physicist specialising in the classical and quantum description of plasmas and radiation.

His research focuses on the radiation reaction and its impact on electron dynamics in strong electromagnetic fields in plasma physics.

After his PhD, Fabien embarked on an entrepreneurial journey by co-founding in 2020, where he works as CTO.

This innovative startup transforms cameras and webcams into medical devices for contactless diagnostics, measuring vital indicators such as heart rate, respiratory rate and blood pressure. This revolutionary technology facilitates remote medical consultations and continuous health monitoring.

Fabien has been recognised for his academic work, with his thesis nominated as outstanding by the University of Sorbonne and published by Springer.

In addition, his work at Quantiq has been recognised with a nomination for the 2022 edition of the BPI's prestigious I-Lab competition.

Lise Alter (1).jpg

Lise Alter

Managing Director of the Agence de l'Innovation en Santé

With over 15 years' experience in the public health sector (Ministry of Health, HAS, CNAM) and the pharmaceutical industry, Dr Lise Alter has a global vision and expertise of the healthcare system and its challenges.

For just over a year, she has been Managing Director of the Agence de l'innovation en santé (Health Innovation Agency) within the Secrétariat Général pour l'Investissement (General Secretariat for Investment) headed by Bruno Bonnell.

In this role, she oversees the health section of France 2030, the Innovation santé 2030 plan, in collaboration with the Ministries of Higher Education and Research, Health and Prevention, and Industry.

Lise Alter is a public health doctor with a master's degree in health services economics and management.

Lise Alter started her career as a medical advisor for "blood, transplants, tissues and cells" at the Directorate-General for Health (Ministry of Health) from 2012 to 2013, then as a medical advisor at the National Health Insurance Fund until 2014. After four years at the Lilly France laboratory (2014-2018) in the "market access" department, then as manager of the oncology business unit, she joined the Ministry of Health's Directorate-General for Healthcare in 2018 as deputy to the deputy director for steering the performance of healthcare providers.

In 2020, Lise Alter is appointed Director of Medical, Economic and Public Health Evaluation at the French National Authority for Health (Haute Autorité de Santé), where she coordinates the work of the departments, in particular to meet the challenges of evaluating tests, treatments and vaccines against Covid-19, and implements a new organisation of the department to meet the challenges of innovation.

Laurence Devillers.jpg

Laurence Devillers is professor of Artificial Intelligence and Ethics at Sorbonne University and the Centre National de la Recherche Scientifique (CNRS-LISN, Paris-Saclay). She is head of the "Affective and social dimensions in oral interaction" research team and of the AI HUMAAINE chair: HUman-MAchine Affective Interaction & Ethics. She is a member of the CNPEN (National Steering Committee for Digital Ethics). She is also a member of AFNOR and JTC21/CEN-CENELEC, responsible for a working group on "Foundational and societal impacts of AI". Laurence Devillers' research interests include emotion detection in audio, nudge strategies, conversational agents and social robots. She has participated in several national and European projects on social and emotional interactions between humans and robots. She is also President of the Blaise Pascal Foundation on mediation in mathematics and computer science. She has written several essays, including "Des robots et des hommes" (Plon, 2017) and "Les robots émotionnels" (L'observatoire, 2020).

Laurence Devillers

Professor at Paris-Sorbonne University

Muriel Dahan (2).png

Muriel Dahan

Director of Research and Development at Unicancer

Muriel Dahan, member of the Académie Française, has a doctorate in pharmacy, a degree in pharmacoepidemiology and is an associate professor.

Her background is in civil society (she ran a pharmacy for 10 years). She joined the senior civil service twenty years ago and has held major responsibilities at the Ministry of Health, the National Cancer Institute (first PTT/RBU, creation of OMEDITs, etc.) and in the ministerial cabinet.

She has led a number of missions and projects that have led to advances, particularly in oncology and in areas related to healthcare products, pharmacy and biology, both in the community and in hospitals. She also teaches, has created a university diploma and has set up a RetexCovid2020 group (see

She recently took part in the interministerial task force on vaccines and was appointed by the Ministers for Health, Research and Industry as a Qualified Representative to lead the Strategic Advisory Board on Healthcare Industries (CSIS 2021), alongside Profs José Alain Sahel and Jean-Charles Soria, Agnès Audier and Lyse Santoro.

The "Innovation Santé 2030" programme announced by the French President on 29 June 2021, with a budget of €7 billion, will implement the many proposals put forward by the CSIS 2021, which are particularly significant both for improving patient health and for boosting France's attractiveness in terms of research, training, access to innovations, production, sovereignty and influence in the healthcare sector.

Muriel Dahan has been Director of Research and Development at Unicancer since the beginning of 2023.


"Xavier Briffault is a researcher in the social sciences and epistemology of mental health at the CNRS. He also holds a doctorate in computer science, and is particularly interested in the applications of digital tools, and especially portable connected objects, in psychiatry and mental health (latest book on the subject: Psychiatrie 3.0 : Être soi et ses connexions, Éditions Doin). Very much involved in translational research, he is or has been a scientific expert for various public (INPES, HAS, Santé Publique France, DGS, HCSP, HCFEA...) and private (Doctopsy, Deuxième, Orpéa...) organizations. Her most recent book concerns the management of children's psychological suffering (Le silence des symptômes, éditions Champ Social, in collaboration with Sébastien Ponnou and Frédérique Chave)".

Xavier Briffault


CNRS researcher

bottom of page